Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clément Desjardins

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Movement Disorders Clinical Practice|August 29, 2025
Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real-World Observational Study (FOSAPO)Clément Desjardins, Quentin Salardaine, Jean-Philippe Brandel, et al.
BMC Neurology|June 4, 2024
Is ethyl chloride the new nitrous oxide? A case reportQuentin Salardaine, Clément Desjardins, Guillaume Baille, et al.
Journal of Parkinson'S Disease|August 14, 2022
Video-Based Automated Assessment of Movement Parameters Consistent with MDS-UPDRS III in Parkinson's DiseaseGaëtan Vignoud, Clément Desjardins, Quentin Salardaine, et al.
Clinical Parkinsonism & Related Disorders|March 24, 2025
Bi-pallidal deep brain stimulation as an effective therapy in atypical two-stage evolution adult-onset <i>KMT2B</i>-related dystoniaGeorges-Junior Kahwagi, Cécile Hubsch, Lydie Burglen, et al.
Journal of Movement Disorders|January 25, 2026
Neuropsychiatric and cognitive safety of subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: insights from a real-world cohortClément Desjardins, Hélène de Saint Vaulry, Quentin Salardaine, et al.
Neurology|October 17, 2025
Nonmotor Symptom Scales in Children With Movement Disorders: A Scoping ReviewClément Desjardins, Christelle Nilles, Hortensia Gimeno, et al.
Movement Disorders Clinical Practice|August 29, 2025
Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case SeriesGuillaume Baille, Nathalie Patte-Karsenti, Quentin Salardaine, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 29, 2024
Digital Outcomes as Biomarkers of Disease Progression in Early Parkinson's Disease: A Systematic ReviewPablo Rábano-Suárez, Natalia Del Campo, Isabelle Benatru, et al.
Journal of Inherited Metabolic Disease|April 9, 2026
Diagnostic Accuracy of Exchangeable Copper for Grading the Severity of Wilson DiseaseClément Desjardins, Nouzha Oussedik-Djebrani, Mickael Alexandre Obadia, et al.
Journal of Medical Genetics|December 23, 2021
Impaired social cognition and fine dexterity in patients with Cowden syndrome associated with germline <i>PTEN</i> variantsClément Desjardins, Frédéric Caux, Bertrand Degos, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Movement Disorders Clinical Practice|August 29, 2025
Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real-World Observational Study (FOSAPO)Clément Desjardins, Quentin Salardaine, Jean-Philippe Brandel, et al.
BMC Neurology|June 4, 2024
Is ethyl chloride the new nitrous oxide? A case reportQuentin Salardaine, Clément Desjardins, Guillaume Baille, et al.
Journal of Parkinson'S Disease|August 14, 2022
Video-Based Automated Assessment of Movement Parameters Consistent with MDS-UPDRS III in Parkinson's DiseaseGaëtan Vignoud, Clément Desjardins, Quentin Salardaine, et al.
Clinical Parkinsonism & Related Disorders|March 24, 2025
Bi-pallidal deep brain stimulation as an effective therapy in atypical two-stage evolution adult-onset <i>KMT2B</i>-related dystoniaGeorges-Junior Kahwagi, Cécile Hubsch, Lydie Burglen, et al.
Journal of Movement Disorders|January 25, 2026
Neuropsychiatric and cognitive safety of subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: insights from a real-world cohortClément Desjardins, Hélène de Saint Vaulry, Quentin Salardaine, et al.
Neurology|October 17, 2025
Nonmotor Symptom Scales in Children With Movement Disorders: A Scoping ReviewClément Desjardins, Christelle Nilles, Hortensia Gimeno, et al.
Movement Disorders Clinical Practice|August 29, 2025
Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case SeriesGuillaume Baille, Nathalie Patte-Karsenti, Quentin Salardaine, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 29, 2024
Digital Outcomes as Biomarkers of Disease Progression in Early Parkinson's Disease: A Systematic ReviewPablo Rábano-Suárez, Natalia Del Campo, Isabelle Benatru, et al.
Journal of Inherited Metabolic Disease|April 9, 2026
Diagnostic Accuracy of Exchangeable Copper for Grading the Severity of Wilson DiseaseClément Desjardins, Nouzha Oussedik-Djebrani, Mickael Alexandre Obadia, et al.
Journal of Medical Genetics|December 23, 2021
Impaired social cognition and fine dexterity in patients with Cowden syndrome associated with germline <i>PTEN</i> variantsClément Desjardins, Frédéric Caux, Bertrand Degos, et al.
Pageof 2